BOSTON, MA and HAMILTON, ONTARIO, October 15, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics),…
Read More
Inaugural Advisory Board Includes Internationally Renowned Experts In Oncology and Radiation Therapy BOSTON, MA and HAMILTON, ONTARIO, July 16, 2018 – Fusion…
BOSTON, MA and HAMILTON, ONTARIO, April 27, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), announced…
Technology will be used to progress Fusion’s pipeline of targeted alpha therapeutics for the treatment of cancers Cambridge, UK and…
HAMILTON, ONTARIO – At the 2018 LSO Annual Awards Presentation event, Fusion Pharmaceuticals was awarded “Life Sciences Company of the Year.” The award recognizes Fusion as an outstanding company which contributed...
Read More
BOSTON, MA and HAMILTON, ONTARIO, February 21, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today…
